Actinium Pharmaceuticals Announces Appointment of Sandesh Seth as Chief Executive Officer
June 09, 2017 07:30 ET
|
Actinium Pharmaceuticals
- Mr. Seth to serve as Chief Executive Officer and Chairman of the Board of Directors - Independent Director Dr. Ajit Shetty appointed to the Company’s Corporate Governance, Audit and Compensation...
Actinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Actimab-A
May 24, 2017 09:22 ET
|
Actinium Pharmaceuticals
- Orphan designation provides increased communication and guidance from regulators and 10-year market exclusivity upon marketing authorization- Actinium’s two leading drug candidates, Iomab-B and...
Actinium Pharmaceuticals Announces Appointment of Hematology Expert Dr. Richard Stone of the Dana-Farber Cancer Institute to its Scientific Advisory Board
May 17, 2017 07:00 ET
|
Actinium Pharmaceuticals
Dr. Stone is a world renowned physician with extensive research and clinical experience focused on refractory leukemia patients and advanced myeloproliferative disordersActinium’s Scientific Advisory...
Actinium Pharmaceuticals Receives Clearance from Health Canada to Initiate Pivotal Phase 3 SIERRA Trial of Iomab-B
May 10, 2017 07:00 ET
|
Actinium Pharmaceuticals
NEW YORK, May 10, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload...
Actinium Pharmaceuticals Announces Sponsorship of the Acute Leukemia Forum 2017
April 18, 2017 07:00 ET
|
Actinium Pharmaceuticals
- Event to bring together worldwide experts to share and discuss latest research that is influencing treatment and management of patients with acute leukemia - Members of Actinium’s...
Actinium Announces Receipt of Positive Scientific Advice from the European Medicines Agency for Iomab-B
March 21, 2017 07:00 ET
|
Actinium Pharmaceuticals
- EMA guidance provides clear regulatory pathway for EU approval for Iomab-B - Trial design, primary endpoint and planned statistical analysis from the Iomab-B U.S. pivotal Phase 3 SIERRA trial...
Actinium Pharmaceuticals Announces Hiring of Steven Price to Position of Vice President, Clinical and Commercial Strategy
February 21, 2017 07:00 ET
|
Actinium Pharmaceuticals
- Industry veteran to lead development of optimized programs for Iomab-B including initiatives targeted at patients, physicians and payors designed to support clinical development and...
Actinium Pharmaceuticals to Attend the BMT Tandem Meetings, the Combined Annual Meetings of Two Leading Transplant Organizations
February 14, 2017 07:00 ET
|
Actinium Pharmaceuticals
- Members of Actinium’s executive and clinical development teams to participate in conference activities and extend the visibility of the Company’s Iomab-B drug candidate to the bone marrow transplant...
Actinium Pharmaceuticals’ Company Presentation at BIO CEO & Investor Conference to Provide Highlights of Recently Announced Actimab-M Trial in Multiple Myeloma
February 13, 2017 07:00 ET
|
Actinium Pharmaceuticals
NEW YORK, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Pharmaceuticals to Present at BIO CEO & Investor Conference
February 09, 2017 07:00 ET
|
Actinium Pharmaceuticals
NEW YORK, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...